Ronald Van Vollenhoven

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. pmc Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden
    Ann Rheum Dis 71:1343-9. 2012
  2. doi request reprint Early start and stop of biologics: has the time come?
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases ClinTRID, The Karolinska Institute, Stockholm 17176, Sweden
    BMC Med 12:25. 2014
  3. doi request reprint Biologics in SLE: towards new approaches
    Ronald F van Vollenhoven
    The Karolinska Institute, Stockholm, Sweden Electronic address
    Best Pract Res Clin Rheumatol 27:341-9. 2013
  4. doi request reprint Challenges and opportunities in SLE clinical trials
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden
    Curr Opin Rheumatol 25:606-15. 2013
  5. doi request reprint Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    Nat Rev Rheumatol 9:510-2. 2013
  6. pmc Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, The Karolinska Institute, Stockholm, Sweden
    Ann Rheum Dis 72:1496-502. 2013
  7. pmc Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study
    Nienke Lesuis
    Medical Faculty, Radboud University, Geert Grooteplein 21, 6500 HB, Nijmegen, The Netherlands
    BMC Med 10:82. 2012
  8. pmc Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis
    Mohammed Mullazehi
    Clinical Immunology, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory C5, Uppsala University, Uppsala, SE 75185, Sweden
    Arthritis Res Ther 14:R100. 2012
  9. doi request reprint Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy
    Ronald F van Vollenhoven
    Department of Medicine, Karolinska Institute, Karolinska University Hospital, Solna Building D1 00, Stockholm SE 17176, Sweden
    Nat Rev Rheumatol 9:70-2. 2013
  10. doi request reprint Rituximab - shadow, illusion or light?
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Sweden
    Autoimmun Rev 11:563-7. 2012

Collaborators

Detail Information

Publications45

  1. pmc Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden
    Ann Rheum Dis 71:1343-9. 2012
    ..To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical efficacy in various patient subsets...
  2. doi request reprint Early start and stop of biologics: has the time come?
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases ClinTRID, The Karolinska Institute, Stockholm 17176, Sweden
    BMC Med 12:25. 2014
    ..In this commentary we will discuss the current treatment paradigm as well as the possibility of an induction-maintenance regimen with biological disease-modifying antirheumatic drugs in early rheumatoid arthritis. ..
  3. doi request reprint Biologics in SLE: towards new approaches
    Ronald F van Vollenhoven
    The Karolinska Institute, Stockholm, Sweden Electronic address
    Best Pract Res Clin Rheumatol 27:341-9. 2013
    ..The overall picture that emerges is one of optimism that advances in SLE therapy will be realised through the targeted use of an increasing number of biologics. ..
  4. doi request reprint Challenges and opportunities in SLE clinical trials
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden
    Curr Opin Rheumatol 25:606-15. 2013
    ..To provide an update on the field of clinical trials in systemic lupus erythematosus (SLE). This review will examine failed and successful clinical trials in SLE in order to draw lessons and determine the optimal ways forward...
  5. doi request reprint Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    Nat Rev Rheumatol 9:510-2. 2013
    ..Methotrexate, which is usually the first-line treatment, elicits good or even excellent clinical results in 20–30% of patients—but in most patients it does not. Thus, an important question is what to do after methotrexate failure...
  6. pmc Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, The Karolinska Institute, Stockholm, Sweden
    Ann Rheum Dis 72:1496-502. 2013
    ..Evaluation of long-term safety of rituximab in rheumatoid arthritis (RA)...
  7. pmc Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study
    Nienke Lesuis
    Medical Faculty, Radboud University, Geert Grooteplein 21, 6500 HB, Nijmegen, The Netherlands
    BMC Med 10:82. 2012
    ..Because treatment differences between men and women could explain the dissimilarities, we investigated gender differences in the disease characteristics before treatment initiation and in the biologic treatment prescribed...
  8. pmc Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis
    Mohammed Mullazehi
    Clinical Immunology, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory C5, Uppsala University, Uppsala, SE 75185, Sweden
    Arthritis Res Ther 14:R100. 2012
    ..We therefore hypothesized that anti-CII are also associated with early erosions...
  9. doi request reprint Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy
    Ronald F van Vollenhoven
    Department of Medicine, Karolinska Institute, Karolinska University Hospital, Solna Building D1 00, Stockholm SE 17176, Sweden
    Nat Rev Rheumatol 9:70-2. 2013
    ..Culminating in the approval of a new therapy in the USA, the year offered new insights for clinicians and fresh hope for patients...
  10. doi request reprint Rituximab - shadow, illusion or light?
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Sweden
    Autoimmun Rev 11:563-7. 2012
    ..In this article I will review the available data and provide some comments that may be of use for the practicing clinician...
  11. pmc Integrated safety in tocilizumab clinical trials
    Michael H Schiff
    Rheumatology Division, University of Colorado School of Medicine, 5400 South Monaco Street, Greenwood Village, CO 80111, USA
    Arthritis Res Ther 13:R141. 2011
    ..Patients from these randomized trials could receive tocilizumab treatment in open-label extension trials. Here, the long-term safety profile of tocilizumab, using pooled data from all of these trials, is reported...
  12. doi request reprint Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden
    Lancet 379:1712-20. 2012
    ..Here we report the 2 year follow-up assessment...
  13. pmc Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA
    Arthritis Res Ther 11:R170. 2009
    ..The objective of this study was to assess the impact of certolizumab pegol (CZP) treatment on health-related quality of life (HRQoL), fatigue and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA)...
  14. pmc Rheumatologists, take heart! We may be doing something right
    Ronald F van Vollenhoven
    Arthritis Res Ther 10:105. 2008
    ..Some methodological issues are discussed, however, and confirmatory studies are suggested...
  15. pmc Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis
    Andreas E R Fasth
    Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Arthritis Res Ther 9:R87. 2007
    ..Together these data imply a primary role for CD4+CD28null T cells in manifestations elsewhere than in the joints of patients with HCMV-seropositive rheumatoid arthritis...
  16. pmc Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis
    Wolfgang Hueber
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, CA 94305, USA
    Arthritis Res Ther 11:R76. 2009
    ..Since no clinical or laboratory tests are available to predict response to anti-TNF therapies, great need exists for predictive biomarkers...
  17. doi request reprint Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial
    R F van Vollenhoven
    Karolinska Institute, Stockholm, Sweden
    Arthritis Rheum 63:1782-92. 2011
    ..To assess the efficacy, safety, and biologic activity of atacicept in tumor necrosis factor antagonist-naive patients with rheumatoid arthritis (RA) in whom the response to methotrexate treatment was inadequate...
  18. doi request reprint Unresolved issues in biologic therapy for rheumatoid arthritis
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Karolinska University Hospital, S 171 76 Stockholm, Sweden
    Nat Rev Rheumatol 7:205-15. 2011
    ..It is concluded that, despite these unresolved issues, important progress has been made and many additional advances in our understanding can be expected during the coming years...
  19. doi request reprint Observational studies: a valuable source for data on the true value of RA therapies
    Ronald F van Vollenhoven
    Clinical Therapy Research, The Karolinska Institute, Stockholm, Sweden
    Clin Rheumatol 30:S19-24. 2011
    ..Observational studies are truly an underappreciated and valuable source of data on the real value of anti-rheumatic therapies, and these data are essential for making sound decisions regarding coverage and reimbursement...
  20. pmc American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial
    R F van Vollenhoven
    Karolinska Institute, Stockholm, Sweden
    Arthritis Care Res (Hoboken) 63:128-34. 2011
    ..We performed a post hoc analysis of a phase III study of certolizumab pegol (Rheumatoid Arthritis Prevention of Structural Damage 1 [RAPID 1]) using the ACR hybrid...
  21. ncbi request reprint New and future agents in the treatment of rheumatoid arthritis
    Ronald F van Vollenhoven
    Department of Rheumatology, The Karolinska Institute, Stockholm 17176, Sweden
    Discov Med 9:319-27. 2010
    ....
  22. doi request reprint Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials
    Ronald F van Vollenhoven
    Karolinska University Hospital, Stockholm, Sweden
    J Rheumatol 37:558-67. 2010
    ..To evaluate the longterm safety of rituximab in clinical trials in patients with rheumatoid arthritis (RA)...
  23. pmc Sex differences in rheumatoid arthritis: more than meets the eye
    Ronald F van Vollenhoven
    Department of Rheumatology, Karolinska University Hospital, 17176 Stockholm, Sweden
    BMC Med 7:12. 2009
    ....
  24. doi request reprint Treatment of rheumatoid arthritis: state of the art 2009
    Ronald F van Vollenhoven
    Rheumatology Unit, Department of Medicine, The Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    Nat Rev Rheumatol 5:531-41. 2009
    ....
  25. doi request reprint Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
    R F van Vollenhoven
    Rheumatology Clinic, Karolinska University Hospital, Stockholm, Sweden
    Lancet 374:459-66. 2009
    ....
  26. doi request reprint The Janus of lupus--benefits and risks with B-cell therapy
    R F van Vollenhoven
    Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden
    Lupus 17:447-9. 2008
    ..I will argue that, while safety data have been rather reassuring so far, vigilance is required; and I will point out three specific mistaken assumptions regarding the safety of B-cell directed therapy in SLE...
  27. ncbi request reprint Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital
    M C Wick
    Department of Rheumatology, Karolinska University Hospital, Solna, Sweden
    Scand J Rheumatol 34:353-8. 2005
    ..e. loss of clinical response in patients who had initially demonstrated clinical response) to infliximab (Remicade) or etanercept (Enbrel)...
  28. ncbi request reprint Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: an observational study
    M C Wick
    Department of Medicine at Karolinska University Hospital, Stockholm, Sweden
    Scand J Rheumatol 33:380-4. 2004
    ..The objective of this study was to identify whether successful clinical disease-control in a Swedish early RA-inception cohort of patients led to an attenuation of radiological progression...
  29. ncbi request reprint Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response
    T Jonsdottir
    Department of Rheumatology, The Karolinska University Hospital, The Karolinska Institutet, Stockholm, Sweden
    Ann Rheum Dis 67:330-4. 2008
    ..To evaluate efficacy, serological responses, and predictors of response in patients with severe and refractory systemic lupus erythematosus (SLE) treated with rituximab plus cyclophosphamide...
  30. ncbi request reprint Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE
    R F van Vollenhoven
    Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden
    Scand J Rheumatol 36:418-23. 2007
    ..To characterize dosages and frequencies of infliximab in a publicly financed health-care system without administrative restrictions on the use of biologics...
  31. doi request reprint Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry)
    J Augustsson
    Department of Medicine, Rheumatology Unit, Karolinska Institute, Karolinska University Hospital Solna, Stockholm SE 171 76, Sweden
    Ann Rheum Dis 69:126-31. 2010
    ..To investigate the effect of tumour necrosis factor (TNF) antagonist treatment on workforce participation in patients with rheumatoid arthritis (RA)...
  32. pmc Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis
    M C Wick
    Rheumatology Unit, Department of Medicine at Karolinska Hospital, Stockholm, Sweden
    Ann Rheum Dis 64:134-7. 2005
    ..To determine if intrapatient comparisons between prediagnosis and subsequent radiological progression could be used to assess effects of DMARDs in an RA inception cohort...
  33. ncbi request reprint Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
    R F van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden
    Scand J Rheumatol 33:423-7. 2004
    ..The monoclonal anti-B cell antibody rituximab (Rituxin, Mabthera) may be of benefit in antibody-driven diseases, including systemic lupus erythematosus (SLE) nephritis...
  34. ncbi request reprint Rheumatoid arthritis registries in Sweden
    R F van Vollenhoven
    Rheumatology Unit, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden
    Clin Exp Rheumatol 23:S195-200. 2005
    ..Data obtained from analyses based on these registries are reviewed. It is concluded that rheumatology registries are excellent tools for improving our knowledge base regarding rheumatic diseases...
  35. pmc Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies
    T Jonsdottir
    Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden
    Ann Rheum Dis 63:1075-8. 2004
    ..To determine the frequency and clinical impact of anticardiolipin antibodies (aCL) in patients with rheumatoid arthritis treated with infliximab and etanercept...
  36. doi request reprint Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort
    K Chatzidionysiou
    Unit for Clinical Research Therapy, Inflammatory Diseases ClinTRID, Karolinska Institute, Stockholm, Sweden
    Scand J Rheumatol 42:190-5. 2013
    ..The purpose of this study was to characterize and compare responses in patients who had failed one tumour necrosis factor (TNF) inhibitor when switching to another TNF inhibitor or rituximab (RTX)...
  37. ncbi request reprint Switching between biological agents
    R F van Vollenhoven
    Department of Rheumatology D1 2, Karolinska University Hospital and Karolinska Institute, 17176 Stockholm, Sweden
    Clin Exp Rheumatol 22:S115-21. 2004
    ..Nonetheless, further attention should be paid to the details of various clinical scenarios in which this question can arise and the methods by which comparisons are made of treatment effects occurring during sequential therapies...
  38. pmc Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description
    M C Wick
    Rheumatology Unit, Department of Medicine, Karolinska Hospital, S 171 76 Stockholm, Sweden
    Ann Rheum Dis 63:848-52. 2004
    ..Joint destruction may result from the cumulative inflammatory burden over time, modified by an individual constant factor...
  39. doi request reprint When to initiate and discontinue biologic treatments for rheumatoid arthritis?
    K Chatzidionysiou
    Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institutet, Stockholm, Sweden
    J Intern Med 269:614-25. 2011
    ..Whereas the former issue has been addressed in a large number of clinical trials and observational studies, the latter remains poorly investigated and is currently the subject of further study...
  40. ncbi request reprint Benefits and risks of biological agents: lymphomas
    R F van Vollenhoven
    Department of Rheumatology D1 2, Karolinska University Hospital and Karolinska Institute, 17176 Stockholm, Sweden
    Clin Exp Rheumatol 22:S122-5. 2004
    ..Current practice recommendations should probably not go further than an awareness of the possibility of lymphoma in any patient with RA exhibiting unexplained systemic symptoms...
  41. pmc CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
    Jennifer Pieper
    Rheumatology Unit, Department of Medicine at Karolinska University Hospital, Karolinska Institute, Solna, Stockholm, Sweden
    BMC Immunol 14:34. 2013
    ..We have performed a mechanism of action study to dissect T cell functionality in RA patients with long-standing disease undergoing abatacept treatment and the influence of ACPA status...
  42. ncbi request reprint Dehydroepiandrosterone in systemic lupus erythematosus
    R F van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden
    Rheum Dis Clin North Am 26:349-62. 2000
    ..The most frequent side effect is mild acneiform dermatitis, and long-term concerns include lowered HDL cholesterol...
  43. pmc Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect
    R F van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, 17176 Stockholm, Sweden
    Ann Rheum Dis 63:426-30. 2004
    ..To determine whether increased infliximab doses result in better clinical outcome in rheumatic diseases...
  44. doi request reprint Pregnancy-associated inflammatory markers are elevated in pregnant women with systemic lupus erythematosus
    S Björkander
    Department of Immunology, The Wenner Gren Institute, Arrhenius Laboratories for Natural Sciences, Stockholm University, Stockholm, Sweden
    Cytokine 59:392-9. 2012
    ..How their children are affected by this heightened inflammatory milieu during pregnancy needs further investigation...
  45. doi request reprint Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases
    T Y T Lu
    Department of Rheumatology, The Karolinska University Hospital, The Karolinska Institutet, Stockholm, Sweden
    Ann Rheum Dis 67:1493-4. 2008